Reuters logo
BRIEF-Antisense Therapeutics says it initiated process for submission of atl1102 for multiple sclerosis phase iib
April 24, 2017 / 1:44 AM / 6 months ago

BRIEF-Antisense Therapeutics says it initiated process for submission of atl1102 for multiple sclerosis phase iib

April 24 (Reuters) - Antisense Therapeutics Ltd

* Initiated process for submission of atl1102 for multiple sclerosis (ms) phase iib ind application with documentation being provided to its regulatory agent in us Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below